{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:41Z","timestamp":1792686101771,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Korean Cardiac Research Foundation"},{"name":"Ministry of Health & Welfare","award":["HC21C0028"],"award-info":[{"award-number":["HC21C0028"]}]},{"name":"Korea government"},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["HI20C1662"],"award-info":[{"award-number":["HI20C1662"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["1711138358"],"award-info":[{"award-number":["1711138358"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["KMDF_PR_20200901_0173"],"award-info":[{"award-number":["KMDF_PR_20200901_0173"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Data on the optimal use of antithrombotic drugs and associated clinical outcomes in patients with atrial fibrillation (AF) and acute ischaemic stroke (IS) are limited. We investigated the prescription patterns of antithrombotics in community practice and long-term clinical prognosis according to early post-stroke antithrombotic therapy in patients with AF and acute IS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Patients with AF who were admitted for acute IS at a single tertiary hospital in 2010\u20132020 were retrospectively reviewed. Clinical profiles including the aetiology of stroke and prescription patterns of antithrombotics were identified. The net clinical outcome (NCO)\u2014the composite of recurrent stroke, any bleeding, hospitalization or emergency department visits for cardiovascular (CV) events, and death\u2014was compared according to the antithrombotic therapy at the first outpatient clinic visit [oral anticoagulation (OAC) alone vs. antiplatelet (APT) alone vs. OAC\/APT(s)] following discharge. A total of 918 patients with AF and acute IS (mean age, 72.6 years; male, 59.3%; mean CHA\u2082DS\u2082-VASc score 3.3) were analysed. One-third (33.9%, n = 310) of patients were simultaneously diagnosed with AF and IS. The most common aetiology of IS was cardioembolism (71.2%), followed by undetermined aetiology (19.8%) and large artery atherosclerosis (6.0%). OAC, APT(s), and concomitant OAC and APT(s) were prescribed in 33.4%, 11.1%, and 53.4% of patients during admission that changed to 67.0%, 9.1%, and 21.7% at the first outpatient clinic, and were mostly continued up to one year after IS. Non-prescription of OAC was observed in 11.3% of post-stroke patients with AF. During a median follow-up of 2.1 years, the overall incidence rate of NCO per 100 patient-year (PY) was 20.14. APT(s) monotherapy presented the highest cumulative risk of NCO (adjusted hazard ratio 1.47, 95% confidence interval 1.08\u20132.00, P = 0.015; with reference to OAC monotherapy) mainly driven by the highest rates of recurrent stroke and any bleeding. OAC\/APT(s) combination therapy was associated with a 1.62-fold significantly higher risk of recurrent stroke (P = 0.040) and marginally higher risk of any bleeding than OAC monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Approximately one-third of acute IS in AF have a distinctive mechanism from cardioembolism. Although APT was frequently prescribed in post-stroke patients with AF, no additive clinical benefit was observed. Adherence to OAC treatment is essential to prevent further CV adverse events in patients with AF and IS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euae033","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T23:06:40Z","timestamp":1706656000000},"source":"Crossref","is-referenced-by-count":7,"title":["Association between antithrombotic therapy after stroke in patients with atrial fibrillation and the risk of net clinical outcome: an observational cohort study"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-0378","authenticated-orcid":false,"given":"Hyo-Jeong","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-5015","authenticated-orcid":false,"given":"So-Ryoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-640X","authenticated-orcid":false,"given":"JungMin","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-6130","authenticated-orcid":false,"given":"Kyung-Yeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-6855","authenticated-orcid":false,"given":"Soonil","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-6372","authenticated-orcid":false,"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-9615","authenticated-orcid":false,"given":"Seil","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"},{"name":"Department of Internal Medicine, Seoul National University College of Medicine , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine , 101 Daehak-ro, Chongno-gu, Seoul 03080 , Republic of Korea"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Chest & Heart Hospital , Liverpool , UK"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2024021623544012500_euae033-B1","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke prevention in atrial fibrillation: a systematic review","volume":"313","author":"Lip","year":"2015","journal-title":"JAMA"},{"key":"2024021623544012500_euae033-B2","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Europace"},{"key":"2024021623544012500_euae033-B3","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B4","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/hs1201.099520","article-title":"Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?","volume":"32","author":"Evans","year":"2001","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"2024021623544012500_euae033-B6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/europace\/euz032","article-title":"Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2024021623544012500_euae033-B7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/eurheartj\/ehx730","article-title":"Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry","volume":"39","author":"Verheugt","year":"2018","journal-title":"Eur Heart J"},{"key":"2024021623544012500_euae033-B8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/0003319718791711","article-title":"Noncardioembolic stroke in patients with atrial fibrillation","volume":"70","author":"Katsi","year":"2019","journal-title":"Angiology"},{"key":"2024021623544012500_euae033-B9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp-2020-325249","article-title":"Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges","volume":"93","author":"Best","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024021623544012500_euae033-B10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000445723","article-title":"Causes of ischemic stroke in patients with non-valvular atrial fibrillation","volume":"42","author":"Nakamura","year":"2016","journal-title":"Cerebrovasc Dis"},{"key":"2024021623544012500_euae033-B11","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B12","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"key":"2024021623544012500_euae033-B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42444-019-0005-0","article-title":"Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database","volume":"20","author":"Park","year":"2019","journal-title":"Int J Arrhythm"},{"key":"2024021623544012500_euae033-B14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024021623544012500_euae033-B16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024021623544012500_euae033-B17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2024021623544012500_euae033-B18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000457809","article-title":"First diagnosis of atrial fibrillation at the time of stroke","volume":"43","author":"Borowsky","year":"2017","journal-title":"Cerebrovasc Dis"},{"key":"2024021623544012500_euae033-B19","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1161\/STROKEAHA.114.006070","article-title":"High prevalence of atrial fibrillation among patients with ischemic stroke","volume":"45","author":"Friberg","year":"2014","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1161\/01.STR.32.3.803","article-title":"Atrial fibrillation and stroke: concepts and controversies","volume":"32","author":"Hart","year":"2001","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cjca.2018.08.036","article-title":"The multiple causes of stroke in atrial fibrillation: thinking broadly","volume":"34","author":"D\u2019Souza","year":"2018","journal-title":"Can J Cardiol"},{"key":"2024021623544012500_euae033-B22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2018.03.027","article-title":"Stroke type and severity in patients with subclinical atrial fibrillation: an analysis from the asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT)","volume":"201","author":"Perera","year":"2018","journal-title":"Am Heart J"},{"key":"2024021623544012500_euae033-B23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2012.04.032","article-title":"Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study","volume":"60","author":"Di Biase","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024021623544012500_euae033-B24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/STROKEAHA.115.012004","article-title":"Atrial fibrillation and mechanisms of stroke: time for a new model","volume":"47","author":"Kamel","year":"2016","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2024021623544012500_euae033-B26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2024021623544012500_euae033-B27","doi-asserted-by":"crossref","first-page":"euad280","DOI":"10.1093\/europace\/euad280","article-title":"Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"2024021623544012500_euae033-B28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024021623544012500_euae033-B29","doi-asserted-by":"crossref","first-page":"euad302","DOI":"10.1093\/europace\/euad302","article-title":"Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF","volume":"25","author":"Guenoun","year":"2023","journal-title":"Europace"},{"key":"2024021623544012500_euae033-B30","doi-asserted-by":"crossref","first-page":"euad288","DOI":"10.1093\/europace\/euad288","article-title":"Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies","volume":"25","author":"Chan","year":"2023","journal-title":"Europace"},{"key":"2024021623544012500_euae033-B31","doi-asserted-by":"crossref","first-page":"e180171","DOI":"10.1001\/jamanetworkopen.2018.0171","article-title":"Prestroke and poststroke antithrombotic therapy in patients with atrial fibrillation: results from a nationwide cohort","volume":"1","author":"Gundlund","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2024021623544012500_euae033-B32","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1161\/STROKEAHA.114.006929","article-title":"Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation","volume":"45","author":"McGrath","year":"2014","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/17474930231158211","article-title":"Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis","volume":"18","author":"Kim","year":"2023","journal-title":"Int J Stroke"},{"key":"2024021623544012500_euae033-B34","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024021623544012500_euae033-B35","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1161\/STROKEAHA.107.504993","article-title":"Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study","volume":"39","author":"Toyoda","year":"2008","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"2024021623544012500_euae033-B37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation","volume":"8","author":"Lip","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2024021623544012500_euae033-B38","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"2024021623544012500_euae033-B39","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/eurheartj\/ehaa218","article-title":"Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source","volume":"42","author":"Ntaios","year":"2021","journal-title":"Eur Heart J"},{"key":"2024021623544012500_euae033-B40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.26654","article-title":"Atrial fibrillation detected before or after stroke: role of anticoagulation","volume":"94","author":"Lyrer","year":"2023","journal-title":"Ann Neurol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euae033\/56484475\/euae033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/2\/euae033\/56676276\/euae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/2\/euae033\/56676276\/euae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T23:55:42Z","timestamp":1708127742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euae033\/7593480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euae033","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,30]]},"article-number":"euae033"}}